Filing Analysis
Avalo Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings press release issued on August 6, 2026.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Avalo Therapeutics, Inc. announced the appointment of Ron Philip to its Board of Directors and his assignment to the Compensation Committee and Science, Development and Commercial Advisory Committee, effective June 23, 2026.
📋 Key Facts
- Ron Philip appointed to the Board effective June 23, 2026.
- Term ends at the 2027 Annual Meeting of Stockholders or until a successor is elected.
- Appointed to the Compensation Committee and Science, Development and Commercial Advisory Committee.
- Granted non-qualified stock options for 40,200 shares of common stock, vesting in three equal annual installments starting June 23, 2026.
- Exercise price is set at the Nasdaq closing price on June 23, 2026.
- Mr. Philip has a high-profile background including CEO roles at Spark Therapeutics and Orbital Therapeutics (acquired by Bristol-Myers Squibb).
Avalo Therapeutics announced the advancement of AVTX-010, a long-acting anti-IL-1β monoclonal antibody targeting hidradenitis suppurativa (HS) and other inflammatory disorders. The company also updated its investor presentation.
📋 Key Facts
- Announcement date: June 16, 2026
- Product focus: AVTX-010, a next-generation anti-IL-1β monoclonal antibody (mAb)
- Target indications: Hidradenitis suppurativa (HS) and additional inflammatory disorders
- Updated investor presentation filed as Exhibit 99.2
Avalo Therapeutics entered into an exchange agreement to create Series C-1 Preferred Stock for an accredited investor and amended employment agreements for four key executives, including the CEO and CFO.
🚩 Red Flags
- Multiple 8-K items in a single filing (3.02, 3.03, 5.02, 5.03), which often indicates a cluster of corporate governance changes.
- Preferential treatment for a specific accredited investor by creating a new class of stock (Series C-1) specifically to bypass previous ownership caps.
📋 Key Facts
- Exchanged 4,294.675 shares of Series C Preferred Stock for 4,294.675 shares of newly created Series C-1 Preferred Stock on June 11, 2026.
- The primary purpose of the Series C-1 creation was to increase the investor's beneficial ownership limit from 4.99% to 9.99% of common stock.
- Series C-1 Preferred Stock is initially convertible into 1,000 shares of Common Stock per share.
- Amended employment agreements for CEO Garry A. Neil, CFO Christopher Sullivan, CMO Mittie Doyle, and CBO Taylor Boyd effective June 12, 2026.
- New severance terms provide 12 months base salary (18 for CEO) for termination without Cause or for Good Reason.
- Change in Control (CiC) provisions include 1.0x base salary (1.5x for CEO) plus 1.0x target bonus and full acceleration of time-based equity awards.
Avalo Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 2, 2026. Stockholders elected seven board members, approved the Second Amended and Restated 2016 Employee Stock Purchase Plan (A&R 2016 ESPP), and ratified Ernst & Young LLP as the independent auditor for fiscal year 2026.
📋 Key Facts
- Annual Meeting held on June 2, 2026, with approximately 85% of outstanding shares (22,672,284 shares) represented.
- Seven board nominees were elected to serve until the 2027 Annual Meeting.
- The A&R 2016 ESPP was approved with 14,513,683 votes 'For' and 6,588,576 votes 'Against'.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Avalo Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a standard disclosure of quarterly performance to the public.
📋 Key Facts
- The report was filed on May 13, 2026, covering the quarter ended March 31, 2026.
- The company utilized Item 2.02 to report results of operations and financial condition.
- A press release was furnished as Exhibit 99.1.
- The filing was signed by Christopher Sullivan, Chief Financial Officer.
Avalo Therapeutics entered into an underwriting agreement to raise approximately $405 million through the sale of common stock and pre-funded warrants. The offering is intended to fund the Phase 3 clinical development of abdakibart and extend the company's cash runway into 2029.
🚩 Red Flags
- Significant dilution: The total offering (including option shares and warrants) of approximately 24.3 million shares represents an 83% increase over the 29.3 million shares outstanding prior to the offering.
📋 Key Facts
- The company agreed to sell 19,730,000 shares of common stock at $17.75 per share.
- The offering includes pre-funded warrants for 1,400,000 shares at $17.749 per warrant.
- Underwriters exercised an option to purchase an additional 3,169,500 shares in full on May 6, 2026.
- Estimated net proceeds are approximately $405.0 million after expenses.
- Preliminary cash, cash equivalents, and short-term investments were approximately $82.0 million as of March 31, 2026.
- The company had 29,326,347 shares of common stock outstanding as of May 4, 2026, prior to this offering.
Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS trial evaluating abdakibart for the treatment of moderate to severe hidradenitis suppurativa. The company reported that the drug met efficacy, safety, and tolerability goals and provided a detailed presentation of the findings.
📋 Key Facts
- The Phase 2 LOTUS trial evaluated abdakibart in patients with moderate to severe hidradenitis suppurativa.
- Topline results were positive regarding efficacy, safety, and tolerability.
- The announcement was made on May 5, 2026, via a press release and a supplemental website presentation.
- Abdakibart is the primary therapeutic candidate discussed in this clinical update.
Avalo Therapeutics entered into an agreement to restructure a $15 million milestone payment related to its acquisition of AlmataBio. The company will pay $2.25 million immediately and holds a 90-day option to buy out the entire $15 million milestone for an additional $5.125 million.
📋 Key Facts
- Agreement signed on April 26, 2026, with the representative of former AlmataBio securityholders.
- The original agreement required a $15 million payment upon the first patient being dosed in a Phase 3 trial.
- Avalo will pay an immediate $2.25 million cash payment within five business days of the effective date.
- Avalo has a 90-day option to pay $5.125 million (in cash, stock, or a mix) to fully satisfy the milestone obligation.
- If the buyout option is not exercised, the milestone payment is adjusted to $12.75 million upon achievement of the Phase 3 event.
- The total buyout cost of $7.375 million represents a significant discount to the original $15 million contingent liability.
Two members of the Board of Directors, Dr. Jonathan Goldman and Mitchell Chan, have notified Avalo Therapeutics of their decision not to stand for re-election at the 2026 Annual Meeting of Stockholders.
📋 Key Facts
- Notification of non-re-election occurred on March 23, 2026.
- Directors involved are Dr. Jonathan Goldman and Mitchell Chan.
- Both directors will continue to serve until the 2026 Annual Meeting.
- The company stated the departures are not the result of any disagreement regarding operations, policies, or practices.
Avalo Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 23, 2026.
📋 Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- A press release detailing these results was issued on March 23, 2026, and furnished as Exhibit 99.1.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Avalo Therapeutics disclosed an updated investor presentation and provided a preliminary estimate of its cash position as of December 31, 2025. The company reports approximately $98 million in cash, cash equivalents, and short-term investments.
📋 Key Facts
- Estimated cash, cash equivalents, and short-term investments: ~$98 million as of Dec 31, 2025.
- The financial information provided is unaudited and preliminary.
- Company updated its investor presentation via its website.
Avalo Therapeutics, Inc. filed an 8-K to announce the posting of an updated investor presentation on its website for use in future investor meetings.
📋 Key Facts
- The company posted an updated Investor Presentation on its website on December 2, 2025.
- The presentation is intended for use in periodic meetings with investors.
- Exhibit 99.1 contains the updated Investor Presentation.
Avalo Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings release issued on November 6, 2025.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release regarding financial results (Exhibit 99.1)
- Signed by Christopher Sullivan, Chief Financial Officer
Avalo Therapeutics announced the completion of patient enrollment for its Phase 2 LOTUS Trial of AVTX-009, targeting the treatment of hidradenitis suppurativa. This is a clinical milestone indicating progress in their drug development pipeline.
📋 Key Facts
- Completion of enrollment for the Phase 2 LOTUS Trial on October 29, 2025.
- The trial focuses on AVTX-009 for the treatment of hidradenitis suppurativa.
- Announcement made via press release (Exhibit 99.1).
Avalo Therapeutics, Inc. filed an 8-K to announce the posting of an updated investor presentation on its website. This is a routine disclosure intended for use in upcoming meetings with potential investors.
📋 Key Facts
- The company released an updated Investor Presentation on October 10, 2025.
- The presentation is intended for periodic use in discussions with investors.
- The filing includes the presentation as Exhibit 99.1.
Avalo Therapeutics, Inc. announced the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025. The filing details his compensation package and professional background in biotech business development.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Taylor Boyd appointed as Chief Business Officer effective October 1, 2025.
- Base salary set at $465,000 per annum.
- Discretionary annual bonus target of up to 40% of base salary.
- Inducement grant of 275,000 stock options vesting over four years (25% after one year, then monthly).
- Boyd brings significant M&A experience, previously at Abzena and Longboard Pharmaceuticals (acquired by Lundbeck for $2.6B).
Avalo Therapeutics announced a change in its Board of Directors, including the appointment of Kevin Lind to the Board and Audit Committee, and the resignation of Dr. June Almenoff.
🚩 Red Flags
- Director resignation (though explicitly stated as unrelated to company operations).
📋 Key Facts
- Kevin Lind appointed to the Board and Audit Committee, effective October 1, 2025.
- Mr. Lind will receive a non-qualified stock option award for 40,200 shares vesting over three years.
- Dr. June Almenoff resigned from the Board and Audit Committee, effective October 1, 2025.
- Dr. Almenoff's equity awards will undergo accelerated vesting in full on October 1, 2025.
- The company stated Dr. Almenoff's resignation is not related to any matter concerning operations, policies, or practice.
Avalo Therapeutics, Inc. filed an 8-K to announce its financial results for the quarterly period ended June 30, 2025.
📋 Key Facts
- The filing reports on Item 2.02: Results of Operations and Financial Condition.
- Financial results were announced via press release on August 7, 2025.
- The reporting period covers the quarter ended June 30, 2025.
Avalo Therapeutics, Inc. filed an 8-K to announce the posting of an updated investor presentation on its website for use in future investor meetings.
📋 Key Facts
- The company posted an updated Investor Presentation on June 20, 2025.
- The presentation is intended for use in periodic meetings with investors.
- The filing includes the presentation as Exhibit 99.1.
Avalo Therapeutics, Inc. announced the appointment of Rita Jain, M.D. to its Board of Directors, effective June 17, 2025. The filing also details the adoption of an Amended and Restated Non-Employee Director Compensation Plan.
📋 Key Facts
- Rita Jain, M.D. appointed to the Board on June 17, 2025.
- Dr. Jain granted a non-qualified stock option award for 40,200 shares of common stock.
- Options vest in three equal annual installments subject to continued service.
- The Company adopted an Amended and Restated Non-Employee Director Compensation Plan effective June 17, 2025.
- Dr. Jain is considered an independent director under Nasdaq and SEC rules.
Avalo Therapeutics held its 2025 Annual Meeting of stockholders on June 17, 2025. The meeting resulted in the election of eight board nominees and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 17, 2025.
- 90% of outstanding shares (approx. 9,787,648 out of 10,827,620) were present or represented by proxy.
- Eight nominees elected to the Board of Directors through the 2026 Annual Meeting.
- Non-binding 'Say-on-Pay' advisory resolution was approved.
- Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
Avalo Therapeutics entered into a new $75.0 million 'at-the-market' (ATM) sales agreement with TD Securities (USA) LLC to facilitate the issuance and sale of common stock. Concurrently, the company terminated its existing $50.0 million sales agreement with Oppenheimer & Co. Inc.
🚩 Red Flags
- Potential dilution: The company is setting up a mechanism to issue up to $75 million in new common stock, which will dilute existing shareholders.
📋 Key Facts
- Entered into a Sales Agreement with TD Securities (USA) LLC on June 5, 2025.
- The new offering has an aggregate price of up to $75.0 million in common stock.
- Commission for TD Cowen is up to 3.0% of gross proceeds.
- The sale will be conducted via 'at the market' (ATM) methods pursuant to Rule 415(a)(4).
- Terminated a previous $50.0 million sales agreement with Oppenheimer & Co. Inc. effective no later than June 4, 2025.
- No termination penalties were incurred for the cancellation of the Oppenheimer agreement.
Avalo Therapeutics, Inc. filed an 8-K to announce the posting of an updated investor presentation on its website. This is a routine disclosure intended for use in meetings with potential investors.
📋 Key Facts
- The company posted an updated Investor Presentation on June 4, 2025.
- The presentation is intended for use in periodic meetings with investors.
- The filing includes the presentation as Exhibit 99.1.
Avalo Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal notification of the release of quarterly earnings data.
📋 Key Facts
- Report date: May 12, 2025
- Reporting period: Quarter ended March 31, 2025
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Signed by Christopher Sullivan, Chief Financial Officer.
Avalo Therapeutics, Inc. filed an 8-K to announce the posting of an updated investor presentation on its website for use in future investor meetings.
📋 Key Facts
- The company released an updated Investor Presentation on May 8, 2025.
- The presentation is intended for periodic use in meetings with investors.
- The filing includes the presentation as Exhibit 99.1.
Avalo Therapeutics, Inc. announced the appointment of Michael Heffernan to its Board of Directors and his designation as Chairman of the Board, effective March 25, 2025. Additionally, the company approved an Amended and Restated Non-Employee Director Compensation Plan.
📋 Key Facts
- Michael Heffernan appointed to the Board of Directors, effective March 25, 2025.
- Mr. Heffernan designated as Chairman of the Board.
- The Board approved an Amended and Restated Non-Employee Director Compensation Plan providing cash and equity compensation for non-employee directors.
- Mr. Heffernan is deemed independent under Nasdaq rules and Rule 10A-3.
Avalo Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- The filing was made on March 20, 2025.
- The report pertains to Item 2.02 (Results of Operations and Financial Condition).
- Financial results cover the year ended December 31, 2024.
Avalo Therapeutics, Inc. filed an 8-K to announce the posting of an updated investor presentation on its website. This is a routine disclosure intended for use in future meetings with investors.
📋 Key Facts
- The company posted an updated Investor Presentation on January 13, 2025.
- The presentation is intended for periodic use in meetings with potential and current investors.
- The filing includes Exhibit 99.1 containing the presentation.
Avalo Therapeutics announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. The filing details her compensation package and a prior consulting relationship with her firm.
🚩 Red Flags
- Related-party transaction: The new officer was a consultant via her own firm (Northbrook Consulting) immediately prior to her employment, receiving $188,000 in fees.
📋 Key Facts
- Jennifer Riley appointed as Chief Strategy Officer effective Jan 1, 2025.
- Base salary set at $450,000 with a target annual bonus of up to 40%.
- Inducement grant of 150,000 stock options vesting over four years.
- Prior relationship: Riley's firm (Northbrook Consulting, LLC) received ~$188,000 for consulting services from July 2024 to Dec 31, 2024.
Avalo Therapeutics, Inc. filed an 8-K to announce the posting of an updated investor presentation on its website. This is a routine disclosure often used by micro-cap biotech companies to communicate clinical or financial updates to the market.
📋 Key Facts
- The company posted an updated Investor Presentation on its website on December 5, 2024.
- The presentation is intended for use in meetings with investors.
- The filing includes Exhibit 99.1 containing the presentation.
Avalo Therapeutics announced the receipt of $69.4 million in gross proceeds following the full exercise of warrants from a March 2024 private placement. The company also updated its investor presentation.
🚩 Red Flags
- Potential dilution for existing common shareholders due to the conversion of Series C Preferred Stock and warrant exercise.
📋 Key Facts
- Received $69.4 million in gross proceeds from the full exercise of warrants issued in March 2024.
- As of November 8, 2024, there are 10,463,633 shares of common stock outstanding.
- There are 24,895.92 shares of Series C Preferred Stock outstanding (convertible at 1,000:1 ratio).
- The company updated its Investor Presentation on November 12, 2024.
Avalo Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Results of Operations and Financial Condition).
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 7, 2024.
- The press release containing the actual financial data is attached as Exhibit 99.1.
Avalo Therapeutics announced the first patient dosing in its Phase 2 LOTUS Trial for AVTX-009, targeting hidradenitis suppurativa. The company also updated its investor presentation.
📋 Key Facts
- First patient dosed in Phase 2 LOTUS Trial of AVTX-009 on October 8, 2024.
- The trial targets the treatment of hidradenitis suppurativa.
- Company released an updated investor presentation for use in future meetings.
Avalo Therapeutics, Inc. filed an 8-K to announce the posting of an updated investor presentation on its website. This is a routine disclosure intended for use in future meetings with investors.
📋 Key Facts
- The company posted an updated Investor Presentation on its website on September 9, 2024.
- The presentation is intended for periodic use in meetings with potential and existing investors.
- The filing includes the presentation as Exhibit 99.1.
Avalo Therapeutics has regained compliance with Nasdaq's Market Value of Listed Securities Standard. This resolves a previous deficiency regarding stockholders' equity that had put the company at risk of delisting.
🚩 Red Flags
- Historical non-compliance with Nasdaq listing rules (Stockholders' Equity Requirement) noted in the filing history.
📋 Key Facts
- On September 3, 2024, Nasdaq confirmed the Company's market value exceeded the $35 million requirement for ten consecutive trading days.
- The Company has regained compliance with Nasdaq Listing Rule 5550(b)(2).
- The matter regarding the previous non-compliance notice issued on May 20, 2024, is now considered closed.
- Previous deficiency was due to failure to maintain $2.5 million in stockholders' equity as of March 31, 2024.
Avalo Therapeutics reported the results of its 2024 Annual Meeting of Stockholders held on August 13, 2024. The meeting resulted in the election of seven directors and the approval of several key shareholder proposals including equity incentive plans.
🚩 Red Flags
- Significant dilution potential: The approval of Proposal 2 allows for the issuance of common stock in exchange for Series C Preferred Stock and warrants, which can lead to significant share dilution for existing common shareholders.
📋 Key Facts
- Stockholders approved the Fourth Amended and Restated 2016 Equity Incentive Plan, increasing reserved shares to 3,548,882.
- Stockholders approved the Amended and Restated Employee Stock Purchase Plan (ESPP), increasing reserved shares to 234,878.
- Seven nominees were elected to the Board of Directors: June Almenoff, Mitchell Chan, Jonathan Goldman, Aaron Kantoff, Gilla Kaplan, Garry Neil, and Samantha Truex.
- Shareholders approved the issuance of common stock related to Series C Preferred Stock, warrants from March 28, 2024, and milestone obligations for AlmataBio, Inc. (Proposal 2).
- Ratification of Ernst & Young LLP as independent auditor for fiscal year ending Dec 31, 2024.
- Quorum was met with approximately 58% of shares present or represented by proxy.
Avalo Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended June 30, 2024.
- Filing date: August 12, 2024.
Avalo Therapeutics received a 180-day extension from Nasdaq to regain compliance with the minimum stockholders' equity requirement. The company currently reports negative stockholders' equity of $112.5 million.
🚩 Red Flags
- Delisting notice/non-compliance with Nasdaq listing rules
- Negative stockholders' equity of $112.5 million (significant insolvency risk)
- Failure to meet alternative compliance requirements (market value or net income)
📋 Key Facts
- Nasdaq issued a notice on May 20, 2024, regarding non-compliance with Listing Rule 5550(b)(1).
- The company reported stockholders' equity of negative $112.5 million as of March 31, 2024.
- Nasdaq granted a 180-day extension on July 29, 2024.
- The deadline to exhibit compliance with the Listing Rule is November 18, 2024.
Avalo Therapeutics, Inc. announced the appointment of Dr. Mittie Doyle as Chief Medical Officer, effective July 15, 2024. The filing details her extensive clinical development background and the terms of her new employment agreement.
📋 Key Facts
- Dr. Mittie Doyle appointed as Chief Medical Officer (CMO) effective July 15, 2024.
- Base salary set at $500,000 per annum.
- Target annual bonus of up to 40% of base salary, payable in cash or vested equity.
- Grant of 234,000 stock options vesting over four years (25% after one year, remainder monthly).
- Severance includes nine months of salary (extended to 12 months in a Change in Control scenario) and accelerated option vesting.
Avalo Therapeutics announced that the Investigational New Drug (IND) application for AVTX-009, an anti-IL-1β monoclonal antibody intended to treat hidradenitis suppurativa (HS), is now active. This marks a significant clinical milestone in the company's development pipeline.
📋 Key Facts
- The IND for AVTX-009 has been declared 'active' as of July 9, 2024.
- AVTX-009 is an anti-IL-1β monoclonal antibody (mAb).
- The target indication for the drug is hidradenitis suppurativa (HS).
Avalo Therapeutics is filing an Amendment No. 2 to its March 8-K to restate audited financial statements and pro forma combined financial information following the acquisition of AlmataBio, Inc. This amendment provides corrected financial data for Almata as of December 31, 2023, and pro forma information for the periods ending March 31, 2024, and December 31, 2023.
🚩 Red Flags
- Restatement of financial information (Item 9.01) following a significant asset acquisition/merger.
📋 Key Facts
- Amendment No. 2 to Form 8-K filed on June 24, 2024.
- Restatement of audited financial statements for AlmataBio, Inc. as of Dec 31, 2023, and from inception (April 28, 2023) to Dec 31, 2023.
- Restatement of unaudited pro forma combined financial information for the three months ended March 31, 2024, and year ended December 31, 2023.
- The filing incorporates consent from Ernst & Young, LLP regarding the audited statements.
Avalo Therapeutics, Inc. announced the appointment of Paul Varki as Chief Legal Officer, effective June 24, 2024. The filing details his extensive pharmaceutical legal background and the specific terms of his employment agreement.
📋 Key Facts
- Paul Varki appointed as Chief Legal Officer on June 24, 2024.
- Base salary is set at $465,000 per year.
- Target discretionary annual bonus of up to 40% of base salary.
- Includes a $50,000 sign-on cash award (subject to 12-month repayment conditions).
- Grant of 150,000 stock options vesting over four years.
- Mr. Varki previously held legal leadership roles at Idorsia Pharmaceuticals US Inc., Amarin Corporation plc, and GlaxoSmithKline.
Avalo Therapeutics, Inc. filed an 8-K to announce the posting of an updated investor presentation on its website for use in future investor meetings.
📋 Key Facts
- The company released an updated Investor Presentation (Exhibit 99.1) on June 24, 2024.
- The filing is categorized under Item 8.01 (Other Events).
- The presentation is intended for use in meetings with potential investors.
Avalo Therapeutics, Inc. filed this 8-K/A to provide the required financial statements and pro forma information following its acquisition of AlmataBio, Inc. The filing includes audited financial statements for Almata and unaudited pro forma condensed combined financial information.
🚩 Red Flags
- None identified in this specific amendment filing.
📋 Key Facts
- The filing is an amendment (8-K/A) to a previous report filed on March 28, 2024.
- Purpose of filing: To satisfy Item 9.01 requirements regarding financial statements and pro forma information for the AlmataBio acquisition.
- Includes audited financial statements of Almata as of December 31, 2023, and for the period from April 28, 2023, to December 31, 2023 (Exhibit 99.1).
- Provides unaudited pro forma condensed combined financial information for the year ended December 31, 2023, and the three months ended March 31, 2024 (Exhibit 99.2).
- The acquisition was completed pursuant to a merger and reorganization agreement.
Avalo Therapeutics received a notice from Nasdaq informing the company that it is no longer in compliance with minimum stockholders' equity requirements. The company reported negative stockholders' equity of $112.6 million as of March 31, 2024.
🚩 Red Flags
- Delisting notice received from Nasdaq
- Significant negative stockholders' equity (-$112.6 million)
- Failure to meet alternative listing requirements (market value or net income)
📋 Key Facts
- Received Nasdaq notice on May 20, 2024.
- Non-compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity.
- Reported stockholders' equity of negative $112.6 million for the period ended March 31, 2024.
- The company has until July 5, 2024, to submit a plan to regain compliance.
- If a plan is accepted, Nasdaq may grant an extension of up to 180 days to evidence compliance.
Avalo Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing serves to incorporate a press release (Exhibit 99.1) regarding financial results.
- Filed by Christopher Sullivan, Chief Financial Officer.
Avalo Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal notice that the company has released its annual earnings via press release.
📋 Key Facts
- Company announced financial results for the year ended December 31, 2023.
- The announcement was made on March 29, 2024.
- Financial results were disseminated via a press release (Exhibit 99.1).
Avalo Therapeutics entered into a merger agreement with AlmataBio, Inc. and simultaneously launched a massive $115.6 million private placement of Series C Preferred Stock. The deal includes significant milestone payments to Almata stockholders and substantial anti-dilution warrants for new investors.
🚩 Red Flags
- Extreme potential dilution: The convertible preferred stock and warrants represent a massive amount of common stock relative to current float.
- Heavy milestone obligations: Up to $27.5 million in future payments (cash or stock) tied to clinical milestones.
- Restrictive covenants: One-year prohibition on subsequent equity financing following the private placement.
- Registration rights penalties: 1.0% monthly penalty if registration statement is not effective within 135 days.
📋 Key Facts
- Acquisition of AlmataBio, Inc. via merger/reorganization completed on March 27, 2024.
- Issuance of $15 million in consideration to Almata stockholders (Common and Series C Preferred Stock).
- Milestone payments totaling up to $27.5 million due to Almata based on cash or stock triggers related to Phase 2/3 trials.
- Private placement of Series C Preferred Stock valued at $115.6 million, convertible into up to ~19.9 million shares of Common Stock.
- Warrants issued for 11.97 million shares with an exercise price of $5.796933 per share.
- Net proceeds from the private placement are expected to be approximately $105 million.
- The company is prohibited from subsequent equity financing for one year or until derivative shares are freely tradeable.
Avalo Therapeutics has regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split. However, the company is now subject to a mandatory one-year panel monitor by Nasdaq.
🚩 Red Flags
- Mandatory panel monitor status (high risk of permanent delisting if price dips again).
- Recent history of reverse stock split to maintain listing.
- Loss of standard cure periods/compliance plans if non-compliance recurs during the monitoring period.
📋 Key Facts
- The Company executed a reverse stock split on December 28, 2023.
- As of January 30, 2024, Nasdaq confirmed the Company has regained compliance with the $1.00 minimum bid price rule.
- Nasdaq has placed the Company under a mandatory panel monitor for one year starting January 30, 2024.
- Any subsequent violation of the Bid Price Rule during this monitoring period will result in immediate delisting proceedings without the opportunity for a compliance plan or cure period.